The crystal structure of 1-(2-iodobenzoyl)-4-(pyrimidin-2-yl)piperazine: a three-dimensional hydrogen-bonded framework, augmented by  $\pi-\pi$ stacking interactions and I···N halogen bonds

Ninganayaka Mahesha,<sup>a</sup> Hemmige S. Yathirajan,<sup>a</sup>\* Tetsundo Furuya,<sup>b</sup> Takashiro Akitsu<sup>b</sup> and Christopher Glidewell<sup>c</sup>

<sup>a</sup>Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysuru-570 006, India, <sup>b</sup>Department of Chemistry, Faculty of Science, Tokyo University of Science, 1-3 Kagurazaka, Shinjuku-ku, Tokyo 162-8601, Japan, and <sup>c</sup>School of Chemistry, University of St Andrews, St Andrews, Fife KY16 9ST, UK. \*Correspondence e-mail: yathirajan@hotmail.com

In 1-(2-iodobenzoyl)-4-(pyrimidin-2-yl)piperazine,  $C_{15}H_{15}IN_4O$ , the central piperazine ring adopts an almost perfect chair conformation with the pyrimidine substituent in an equatorial site. The planar amide unit makes a dihedral angle of 80.44 (7)° with the phenyl ring. A combination of  $C-H\cdots O$  and  $C-H\cdots \pi$ (arene) hydrogen bonds links the molecules into a complex three-dimensional network structure, augmented by a  $\pi-\pi$  stacking interaction and an I···N halogen bond, all involving different pairs of inversion-related molecules. Comparisons are made with the structures of a number of related compounds.

### 1. Chemical context

Pyrimidine derivatives are well represented amongst the range of heterocyclic compounds that exhibit a broad spectrum of biological activities such as analgesic and anti-inflammatory activity (Amin et al., 2009), antibacterial (Kuyper et al., 1996), antidepressant (Kim et al., 2010), antimicrobial and antioxidant (Padmaja et al., 2009) and antiviral activities (Ibrahim & El-Metwally, 2010). Piperazine-based compounds also exhibit anti-cancer properties (Abdel-Jalil et al., 2005), while the combination of pyrimidine and piperazine units is found in buspirone, 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione (Tollefson et al., 1991), which can be used in the treatment of anxiety. With these considerations in mind, we have now synthesized the title compound (I) (Fig. 1), and we report here its molecular and supramolecular structure. Compound (I) was prepared by reaction of 1-(2pyrimidyl)piperazine with 2-iodobenzoic acid in the presence of dimethylaminopropyl)-3-ethylcarbodimide as the dehydrating agent.





Received 17 December 2018 Accepted 20 December 2018

Edited by M. Weil, Vienna University of Technology, Austria

Keywords: pyrimidine; piperazine; crystal structure; molecular conformation; hydrogen bonding; supramolecular assembly.

CCDC reference: 1886570

**Supporting information**: this article has supporting information at journals.iucr.org/e



OPEN  $\widehat{\bigcirc}$  ACCESS



Figure 1 The molecular structure of compound (I) showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.

### 2. Structural commentary

Within the molecule of compound (I) (Fig. 1), the piperazine ring adopts an almost perfect chair conformation. The ringpuckering parameters, calculated for the atom sequence (N1, C2, C3, N4, C5, C6) are Q = 0.557 (3) Å,  $\theta = 1.2$  (3) ° and  $\varphi =$ 258 (14)°, while for an idealized chair form the value of  $\theta$  is 0.0° (Boeyens, 1978). The pyrimidine substituent at the pyramidal atom N4 occupies an equatorial site, but the amidic unit at atom N1 is effectively planar, and the r.m.s. deviation from the mean plane of atoms (C2, N1, C6, C17, O17 and C11) is only 0.027 Å. The dihedral angle between this plane and the aryl ring (C11–C16) is 80.44 (7)°. The molecules of (I) thus exhibit no internal symmetry and so are conformationally chiral, as confirmed by the centrosymmetric space group in which the molecule crystallizes.

### 3. Supramolecular features

The supramolecular assembly of compound (I) is built from two C-H···O hydrogen bonds, involving the aryl and pyrimidyl atoms C16 and C45 as the donors (Table 1), and one C-H··· $\pi$ (arene) hydrogen bond: there is a further intermolecular C-H···O contact, involving atom C13, but here the D-H···A angle is less than 140°, and so this contact cannot be regarded as structurally significant (Wood *et al.*, 2009). There are also present in the structure a  $\pi$ - $\pi$  stacking interaction between pairs of pyrimidine rings and an I···N halogen bond.

The hydrogen bonds give rise to a three-dimensional network structure of considerable complexity, but this is readily analysed in terms of three one-dimensional substructures (Ferguson *et al.*, 1998*a,b*; Gregson *et al.*, 2000). The action of the two C-H···O hydrogen bonds in combination links molecules related by inversion and translation into a chain of edge-fused rings running parallel to the [001] direction (Fig. 2), in which  $R_2^2(10)$  (Etter, 1990; Etter *et al.*, 1990; Bernstein *et al.*, 1995) rings centred at (0.5, 0.5, n + 0.5) alternate with  $R_4^2(28)$  rings centred at (0.5, 0.5, n), where n represents an integer in each case.

Table 1		_	
Hydrogen-bond	geometry	(Å,	°).

# Cg1 is the centroid of the C11-C16 ring.

$D - H \cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - \mathbf{H} \cdot \cdot \cdot A$
$C16-H16\cdots O17^{i}$	0.95	2.50	3.395 (3)	157
$C45-H45\cdots O17^{ii}$	0.95	2.57	3.508 (3)	169
$C46-H46\cdots Cg1^{iii}$	0.95	2.72	3.596 (3)	153

Symmetry codes: (i) -x + 1, -y + 1, -z + 1; (ii) x, y, z + 1; (iii)  $-x + \frac{1}{2}$ ,  $y + \frac{1}{2}$ ,  $-z + \frac{3}{2}$ .

A second sub-structure can be identified in which the C– H $\cdots \pi$ (arene) hydrogen bond links molecules related by a 2<sub>1</sub> screw axis to form a chain running parallel to the [010] direction (Fig. 3). The chains parallel to [010] and [001] each



Figure 2

Part of the crystal structure of compound (I) showing the formation of a hydrogen-bonded chain of edge-fused rings parallel to the [001] direction. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, the H atoms not involved in the motif shown have been omitted. The I atoms marked with an asterisk (\*), a hash (#) or a dollar sign (\$) are at the symmetry positions (1 - x, 1 - y, 1 - z), (x, y, 1 + z) and (1 - x, 1 - y, 2 - z), respectively.

use only one type of hydrogen bond, but the alternating action of the C-H···O and C-H··· $\pi$ (arene) hydrogen bonds involving atoms C16 and C46 as the donors (Table 1) links the molecules into a chain of rings running parallel to the [ $\overline{111}$ ] direction (Fig. 4). The combination of chains running parallel to [010], [001] and [ $\overline{111}$ ] suffices to generate a continuous three-dimensional network structure.

The formation of the hydrogen-bonded network is augmented by two further intermolecular interactions, each of which involves inversion related pairs of molecules. The pyrimidine rings of the molecules at (x, y, z) and (1 - x, 1 - y, 2 - z), which are components of the hydrogen-bonded chain along [001], are strictly parallel with an interplanar spacing of 3.4295 (10) Å and a ring-centroid separation of 3.4924 (6) Å, thus giving rise to a  $\pi$ - $\pi$  stacking interaction (Fig. 5). Finally, we note a short intermolecular I···N contact with geometrical parameters of I12···N41<sup>i</sup> = 3.168 (2) Å and C12-I12···N41<sup>i</sup> 174.83 (7)° [symmetry code: (i) -x, 1 - y, 1 - z], which can be regarded as a halogen bond (Gilday *et al.*, 2015; Cavallo *et al.*, 2016).

### 4. Database survey

It is of interest briefly to compare the structure of compound (I) reported here with those of some related structures which have been recently reported. In  $2-\{4-[(1,3-benzodioxol-5-$ 



yl)methyl]piperazin-1-yl]pyrimidine (II), the molecules are linked into sheets by a combination of  $C-H\cdots\pi(arene)$  and  $C-H\cdots\pi$ (pyrimidine) hydrogen bonds (Wu *et al.*, 2013). N-(4-Chlorophenyl)-4-(pyrimidin-2-yl)piperazine-1-carboxamide (III) crystallizes with Z' = 2 in space group  $P2_1/c$  (Li, 2011b), and the molecules are linked into chains by two independent N-H···O hydrogen bonds: these chains, parallel to [100], are of the  $C_2^2(8)$  type rather than of the C(4) type as originally reported. However, the original report overlooked the presence of  $C-H \cdots O$  hydrogen bonds which, in combination with the N-H···O hydrogen bond within the selected asymmetric unit, generates a second chain, this time running parallel to the [010] direction (Fig. 6), so that overall the supramolecular assembly takes the form of a sheet parallel to (001). In the simpler analogue N-(4-chlorophenyl)-4methylpiperidine-1-carboxamide (IV), the assembly was reported (Li, 2011a) as consisting of simple C(4) chains built from N-H···O hydrogen bonds. However, the presence in (IV) of a C-H···O hydrogen bond was overlooked, and the two hydrogen bonds together generate a complex sheet structure lying parallel to (100) (Fig. 7). Finally, we note also the structures of a number of salts of the 4-(pyrimidin-2yl)piperazin-1-ium cation, including the chloride and nitrate





Figure 3

Part of the crystal structure of compound (I) showing the formation of a hydrogen-bonded chain parallel to the [010] direction. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, the H atoms not involved in the motif shown have been omitted. The I atoms marked with an asterisk (\*), a hash (#) or a dollar sign (\$) are at the symmetry positions  $(\frac{1}{2} - x, \frac{1}{2} + y, \frac{3}{2} - z), (\frac{1}{2} - x, -\frac{1}{2} + y, \frac{3}{2} - z)$  and (x, 1 + y, z), respectively.

Part of the crystal structure of compound (I) showing the formation of a hydrogen-bonded chain of rings parallel to the [ $\overline{1}11$ ] direction. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, the H atoms not involved in the motif shown have been omitted. The I atoms marked with an asterisk (\*), a hash (#), a dollar sign (\$), an ampersand (&) or a percent sign (%) are at the symmetry positions  $(1 - x, 1 - y, 1 - z), (\frac{1}{2} - x, \frac{1}{2} + y, \frac{3}{2} - z), (-\frac{1}{2} + x, \frac{3}{2} - y, \frac{1}{2} + z), (\frac{1}{2} + x, \frac{1}{2} - y, -\frac{1}{2} + z)$  and  $(1.5 - x, -\frac{1}{2} + y, \frac{1}{2} - z)$  respectively.



#### Figure 5

Part of the crystal structure of compound (I) showing the  $\pi$ - $\pi$  stacking interaction between adjacent pyrimidine rings. For the sake of clarity, the unit-cell outline and the H atoms have been omitted. The I atom marked with an asterisk (\*) is at the symmetry position (1 - x, 1 - y, 2 - z).



#### Figure 6

Part of the crystal structure of compound (III) showing the formation of a hydrogen-bonded chain parallel to [010]. The original atomic coordinates (Li, 2011*b*) have been used and, for the sake of clarity, the H atoms not involved in the motif shown have been omitted.

(Yamuna *et al.*, 2014*a*), the hydrogenfumarate (Yamuna *et al.*, 2014*b*) and the butanoate (Yamuna *et al.*, 2014*c*).

### 5. Synthesis and crystallization

1-(2-Pyrimidyl)piperazine was purchased from Sigma-Aldrich. For the synthesis of compound (I), 1-(3-dimethylaminopropyl)-3-ethylcarbodimide (52 mg, 0.6 mmol), 1-hydroxybenzotriazole (81 mg, 0.6 mmol) and triethylamine (0.5 ml, 1.8 mmol) were added to a solution of 2-iodobenzoic acid (0.6 mmol) in N.N-dimethylformamide (5 ml) and the resulting mixture stirred for 20 mins at 273 K. A solution of 1-(2-pyrimidyl)piperazine (100 mg, 0.6 mmol) in N.N-dimethylformamide (5 ml) was then added and stirring was continued overnight at ambient temperature. The reaction was confirmed to be complete using thin-layer chromatography, and the mixture was then quenched with water (10 ml) and extracted with ethyl acetate (20 ml). The organic layer was separated and washed successively with an aqueous hydrochloric acid solution  $(1 \text{ mol } dm^{-3})$ , a saturated solution of sodium hydrogencarbonate and then with brine. The organic phase was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. Crystals suitable for single-crystal X-ray diffraction were grown by slow evaporation, at ambient temperature and in the presence of air, of a solution in methanol; m. p. 450-452 K.





Part of the crystal structure of compound (IV) showing the formation of a hydrogen-bonded sheet parallel to (100). The original atomic coordinates (Li, 2011*a*) have been used and, for the sake of clarity, the H atoms not involved in the motif shown have been omitted.

 Table 2

 Experimental details.

Crystal data	
Chemical formula	$C_{15}H_{15}IN_4O$
M <sub>r</sub>	394.21
Crystal system, space group	Monoclinic, $P2_1/n$
Temperature (K)	173
<i>a</i> , <i>b</i> , <i>c</i> (Å)	9.6417 (17), 13.604 (2), 12.174 (2)
$\beta$ (°)	105.155 (2)
$V(Å^3)$	1541.3 (4)
Z	4
Radiation type	Μο Κα
$\mu (\text{mm}^{-1})$	2.08
Crystal size (mm)	$0.67 \times 0.56 \times 0.16$
Data collection	
Diffractometer	Bruker APEXII CCD
Absorption correction	Multi-scan ( <i>SADABS</i> ; Bruker, 2015)
$T_{\min}, T_{\max}$	0.345, 0.717
No. of measured, independent and observed $[I > 2\sigma(I)]$ reflections	8152, 3452, 3188
R <sub>int</sub>	0.067
$(\sin \theta / \lambda)_{\max} ( \text{\AA}^{-1} )$	0.652
Refinement	
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.028, 0.075, 1.05
No. of reflections	3452
No. of parameters	190
H-atom treatment	H-atom parameters constrained
$\Delta \rho_{\rm max},  \Delta \rho_{\rm min}  ({ m e} \ { m \AA}^{-3})$	0.96, -0.74

Computer programs: APEX2 (Bruker, 2004), SAINT (Bruker, 2015), SHELXT (Sheldrick, 2015a), SHELXL2014 (Sheldrick, 2015b) and PLATON (Spek, 2009).

### 6. Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2. All H atoms were located in difference maps, and they were subsequently treated as riding atoms in geometrically idealized positions with C–H distances of 0.95 Å (aromatic) or 0.99 Å (CH<sub>2</sub>), and with  $U_{iso}(H) = 1.2U_{eq}(C)$ .

### Acknowledgements

NM is grateful to the University of Mysore for research facilities.

### **Funding information**

HSY is grateful to the UGC, New Delhi for the award of a BSR Faculty Fellowship for three years.

References

- Abdel-Jalil, R. J., Aldoqum, H. M., Ayoub, M. T. & Voeller, W. (2005). *Heterocycles*, **65**, 2061–2070.
- Amin, K. M., Hanna, M. M., Abo-Youssef, H. E. & George, R. F. (2009). Eur. J. Med. Chem. 44, 4572–4584.
- Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). Angew. Chem. Int. Ed. Engl. 34, 1555–1573.
- Boeyens, J. C. A. (1978). J. Cryst. Mol. Struct. 8, 317-320.
- Bruker (2004). APEX2. Bruker AXS Inc., Madison, Wisconsin, USA.Bruker (2015). SADABS and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
- Cavallo, G., Metrangolo, P., Milani, R., Pilati, T., Priimagi, A., Resnati, G. & Terraneo, G. (2016). *Chem. Rev.* **116**, 2478–2601.
- Etter, M. (1990). Acc. Chem. Res. 23, 120-126.
- Etter, M. C., MacDonald, J. C. & Bernstein, J. (1990). Acta Cryst. B46, 256–262.
- Ferguson, G., Glidewell, C., Gregson, R. M. & Meehan, P. R. (1998a). Acta Cryst. B54, 129–138.
- Ferguson, G., Glidewell, C., Gregson, R. M. & Meehan, P. R. (1998b). Acta Cryst. B54, 139–150.
- Gilday, L. C., Robinson, S. W., Barendt, T. A., Langton, M. J., Mullaney, B. R. & Beer, P. D. (2015). *Chem. Rev.* 115, 7118– 7195.
- Gregson, R. M., Glidewell, C., Ferguson, G. & Lough, A. J. (2000). Acta Cryst. B56, 39–57.
- Ibrahim, D. A. & El-Metwally, A. M. (2010). Eur. J. Med. Chem. 45, 1158–1166.
- Kim, J. Y., Kim, D., Kang, S. Y., Park, W.-K., Kim, H. J., Jung, M. E., Son, E.-J., Pae, A. N., Kim, J. & Lee, J. (2010). *Bioorg. Med. Chem. Lett.* 20, 6439–6442.
- Kuyper, L. F., Garvey, J. M., Baccanari, D. P., Champness, J. N., Stammers, D. K. & Beddell, C. R. (1996). *Bioorg. Med. Chem.* 4, 593–602.
- Li, Y.-F. (2011a). Acta Cryst. E67, o1796.
- Li, Y.-F. (2011b). Acta Cryst. E67, o2575.
- Padmaja, A., Payani, T., Reddy, G. D. & Padmavathi, V. (2009). Eur. J. Med. Chem. 44, 4557–4566.
- Sheldrick, G. M. (2015a). Acta Cryst. A71, 3-8.
- Sheldrick, G. M. (2015b). Acta Cryst. C71, 3-8.
- Spek, A. L. (2009). Acta Cryst. D65, 148-155.
- Tollefson, G. D., Lancaster, S. P. & Montague-Clouse, J. (1991). Psychopharmacol. Bull. 27, 163–170.
- Wood, P. A., Allen, F. H. & Pidcock, E. (2009). CrystEngComm, 11, 1563–1571.
- Wu, C., Li, J., Wei, H., Hang, Y. & Jiang, Y. (2013). Acta Cryst. E69, 01140.
- Yamuna, T. S., Jasinski, J. P., Kaur, M., Anderson, B. J. & Yathirajan, H. S. (2014a). Acta Cryst. E70, 203–206.
- Yamuna, T. S., Jasinski, J. P., Kaur, M., Anderson, B. J. & Yathirajan, H. S. (2014c). Acta Cryst. E70, o1063–o1064.
- Yamuna, T. S., Kaur, M., Jasinski, J. P. & Yathirajan, H. S. (2014b). Acta Cryst. E70, 0702–0703.

# supporting information

# Acta Cryst. (2019). E75, 129-133 [https://doi.org/10.1107/S205698901801811X]

The crystal structure of 1-(2-iodobenzoyl)-4-(pyrimidin-2-yl)piperazine: a threedimensional hydrogen-bonded framework, augmented by  $\pi$ - $\pi$  stacking interactions and I···N halogen bonds

# Ninganayaka Mahesha, Hemmige S. Yathirajan, Tetsundo Furuya, Takashiro Akitsu and Christopher Glidewell

# **Computing details**

Data collection: *APEX2* (Bruker, 2004); cell refinement: *SAINT* (Bruker, 2015); data reduction: *SAINT* (Bruker, 2015); program(s) used to solve structure: SHELXT (Sheldrick, 2015a); program(s) used to refine structure: *SHELXL2014* (Sheldrick, 2015b); molecular graphics: *PLATON* (Spek, 2009); software used to prepare material for publication: *SHELXL2014* (Sheldrick, 2015b) and *PLATON* (Spek, 2009).

1-(2-lodobenzoyl)-4-(pyrimidin-2-yl)piperazine

## Crystal data

C<sub>15</sub>H<sub>15</sub>IN<sub>4</sub>O  $M_r = 394.21$ Monoclinic, P2<sub>1</sub>/n a = 9.6417 (17) Å b = 13.604 (2) Å c = 12.174 (2) Å  $\beta = 105.155 (2)^{\circ}$   $V = 1541.3 (4) \text{ Å}^3$ Z = 4

## Data collection

Bruker APEXII CCD diffractometer Radiation source: fine focus sealed tube Graphite monochromator Detector resolution: 0.3333 pixels mm<sup>-1</sup>  $\varphi$  and  $\omega$  scans Absorption correction: multi-scan (*SADABS*; Bruker, 2015)  $T_{\min} = 0.345$ ,  $T_{\max} = 0.717$ 

### Refinement

Refinement on  $F^2$ Least-squares matrix: full  $R[F^2 > 2\sigma(F^2)] = 0.028$  $wR(F^2) = 0.075$ S = 1.05 F(000) = 776  $D_x = 1.699 \text{ Mg m}^{-3}$ Mo K $\alpha$  radiation,  $\lambda = 0.71073 \text{ Å}$ Cell parameters from 3152 reflections  $\theta = 2.3-27.6^{\circ}$   $\mu = 2.08 \text{ mm}^{-1}$  T = 173 KPlate, colour  $0.67 \times 0.56 \times 0.16 \text{ mm}$ 

8152 measured reflections 3452 independent reflections 3188 reflections with  $I > 2\sigma(I)$  $R_{int} = 0.067$  $\theta_{max} = 27.6^{\circ}, \theta_{min} = 2.3^{\circ}$  $h = -12 \rightarrow 10$  $k = -17 \rightarrow 16$  $l = -15 \rightarrow 15$ 

3452 reflections190 parameters0 restraintsHydrogen site location: inferred from neighbouring sites

H-atom parameters constrained	$(\Delta/\sigma)_{\rm max} = 0.001$
$w = 1/[\sigma^2(F_o^2) + (0.0235P)^2 + 0.7279P]$	$\Delta  ho_{ m max} = 0.96 \ { m e} \ { m \AA}^{-3}$
where $P = (F_o^2 + 2F_c^2)/3$	$\Delta \rho_{\rm min} = -0.74 \text{ e } \text{\AA}^{-3}$

Special details

**Geometry**. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters  $(Å^2)$ 

	x	У	Ζ	$U_{\rm iso}*/U_{\rm eq}$
N1	0.2388 (2)	0.44984 (14)	0.52539 (16)	0.0253 (4)
C2	0.2263 (3)	0.36447 (15)	0.5950 (2)	0.0282 (6)
H2A	0.2567	0.3046	0.5613	0.034*
H2B	0.1248	0.3559	0.5964	0.034*
C3	0.3195 (3)	0.37777 (17)	0.7159 (2)	0.0290 (6)
H3A	0.3033	0.3225	0.7640	0.035*
H3B	0.4222	0.3777	0.7159	0.035*
N4	0.2839 (2)	0.47043 (14)	0.76229 (16)	0.0260 (4)
C5	0.2977 (3)	0.55610 (16)	0.69257 (18)	0.0247 (5)
H5A	0.3991	0.5637	0.6904	0.030*
H5B	0.2689	0.6163	0.7265	0.030*
C6	0.2028 (3)	0.54263 (17)	0.57233 (19)	0.0273 (5)
H6A	0.1005	0.5421	0.5735	0.033*
H6B	0.2174	0.5980	0.5239	0.033*
C17	0.2929 (3)	0.45026 (16)	0.43404 (17)	0.0211 (4)
O17	0.3118 (2)	0.52552 (12)	0.38448 (14)	0.0334 (4)
C11	0.3328 (3)	0.35268 (15)	0.39109 (19)	0.0195 (5)
C12	0.2434 (2)	0.30692 (15)	0.29625 (17)	0.0191 (4)
I12	0.03709 (2)	0.36186 (2)	0.21850 (2)	0.02547 (8)
C13	0.2883 (3)	0.22226 (16)	0.25098 (19)	0.0257 (5)
H13	0.2268	0.1909	0.1867	0.031*
C14	0.4237 (3)	0.18428 (17)	0.3008 (2)	0.0327 (6)
H14	0.4553	0.1269	0.2699	0.039*
C15	0.5130 (3)	0.22889 (19)	0.3947 (2)	0.0346 (6)
H15	0.6054	0.2021	0.4284	0.042*
C16	0.4677 (3)	0.31314 (18)	0.4401 (2)	0.0279 (5)
H16	0.5293	0.3438	0.5048	0.033*
N41	0.2769 (2)	0.57158 (16)	0.91400 (17)	0.0301 (5)
C42	0.3025 (2)	0.48172 (17)	0.87784 (18)	0.0221 (4)
N43	0.3414 (2)	0.40176 (15)	0.94349 (17)	0.0280 (4)
C44	0.3528 (3)	0.4150 (2)	1.0545 (2)	0.0328 (6)
H44	0.3790	0.3601	1.1039	0.039*
C45	0.3288 (3)	0.5033 (2)	1.1012 (2)	0.0318 (6)
H45	0.3381	0.5108	1.1804	0.038*
C46	0.2902 (3)	0.5804 (2)	1.0258 (2)	0.0338 (6)
H46	0.2721	0.6427	1.0546	0.041*

# supporting information

	$U^{11}$	$U^{22}$	$U^{33}$	$U^{12}$	$U^{13}$	$U^{23}$
N1	0.0418 (12)	0.0171 (8)	0.0180 (9)	0.0026 (9)	0.0095 (8)	-0.0025 (7)
C2	0.0455 (17)	0.0190 (11)	0.0247 (13)	-0.0072 (10)	0.0172 (12)	-0.0029 (8)
C3	0.0496 (17)	0.0193 (10)	0.0211 (12)	0.0030 (12)	0.0149 (11)	0.0016 (9)
N4	0.0421 (12)	0.0213 (9)	0.0161 (9)	0.0009 (10)	0.0101 (8)	-0.0012 (7)
C5	0.0377 (13)	0.0191 (10)	0.0182 (11)	0.0013 (11)	0.0088 (9)	-0.0022 (8)
C6	0.0411 (14)	0.0223 (10)	0.0181 (10)	0.0059 (11)	0.0069 (10)	-0.0043 (9)
C17	0.0304 (11)	0.0176 (9)	0.0124 (9)	0.0005 (10)	0.0007 (8)	-0.0020 (8)
O17	0.0646 (13)	0.0173 (7)	0.0196 (8)	0.0013 (9)	0.0133 (8)	0.0014 (6)
C11	0.0302 (12)	0.0145 (9)	0.0150 (10)	-0.0006 (9)	0.0079 (9)	0.0014 (7)
C12	0.0263 (11)	0.0174 (9)	0.0153 (9)	-0.0017 (9)	0.0084 (8)	0.0003 (8)
I12	0.02670 (12)	0.02407 (11)	0.02409 (11)	-0.00088(5)	0.00387 (8)	-0.00347 (5)
C13	0.0421 (14)	0.0163 (10)	0.0218 (11)	-0.0010 (11)	0.0141 (10)	-0.0016 (8)
C14	0.0491 (16)	0.0192 (11)	0.0374 (14)	0.0070 (12)	0.0250 (12)	0.0005 (10)
C15	0.0345 (13)	0.0304 (13)	0.0408 (14)	0.0108 (13)	0.0132 (11)	0.0083 (11)
C16	0.0313 (12)	0.0261 (11)	0.0238 (11)	0.0009 (11)	0.0031 (9)	0.0020 (9)
N41	0.0378 (12)	0.0343 (11)	0.0186 (10)	0.0082 (10)	0.0081 (8)	-0.0043 (8)
C42	0.0214 (10)	0.0286 (11)	0.0174 (10)	-0.0028 (10)	0.0070 (8)	-0.0009(9)
N43	0.0368 (12)	0.0279 (10)	0.0214 (10)	-0.0055 (10)	0.0115 (8)	0.0019 (8)
C44	0.0384 (14)	0.0388 (14)	0.0224 (12)	-0.0092 (13)	0.0099 (10)	0.0063 (10)
C45	0.0351 (13)	0.0452 (14)	0.0169 (11)	-0.0073 (13)	0.0098 (9)	-0.0023 (10)
C46	0.0400 (14)	0.0428 (14)	0.0199 (12)	0.0034 (13)	0.0102 (10)	-0.0060 (11)

Atomic displacement parameters  $(Å^2)$ 

# Geometric parameters (Å, °)

N1—C17	1.346 (3)	C11—C12	1.394 (3)	
N1-C2	1.461 (3)	C12—C13	1.393 (3)	
N1-C6	1.464 (3)	C12—I12	2.104 (2)	
C2—C3	1.521 (4)	C13—C14	1.388 (4)	
C2—H2A	0.9900	C13—H13	0.9500	
C2—H2B	0.9900	C14—C15	1.379 (4)	
C3—N4	1.459 (3)	C14—H14	0.9500	
С3—НЗА	0.9900	C15—C16	1.391 (3)	
С3—Н3В	0.9900	C15—H15	0.9500	
N4—C42	1.379 (3)	C16—H16	0.9500	
N4—C5	1.468 (3)	N41—C46	1.339 (3)	
C5—C6	1.521 (3)	N41—C42	1.344 (3)	
C5—H5A	0.9900	C42—N43	1.344 (3)	
C5—H5B	0.9900	N43—C44	1.340 (3)	
С6—Н6А	0.9900	C44—C45	1.375 (4)	
С6—Н6В	0.9900	C44—H44	0.9500	
C17—O17	1.226 (3)	C45—C46	1.380 (4)	
C17—C11	1.513 (3)	C45—H45	0.9500	
C11—C16	1.390 (3)	C46—H46	0.9500	
C17_N1_C2	126 25 (18)	C16—C11—C12	119 3 (2)	
$C_{1}$ $C_{1}$ $C_{2}$	120.25(10)	CIO CII - CI2	117.5 (2)	

C17—N1—C6	120.10 (19)	C16—C11—C17	119.1 (2)
C2—N1—C6	113.23 (17)	C12—C11—C17	121.3 (2)
N1—C2—C3	110.4 (2)	C13—C12—C11	120.5 (2)
N1—C2—H2A	109.6	C13—C12—I12	118.05 (18)
C3—C2—H2A	109.6	C11—C12—I12	121.41 (16)
N1—C2—H2B	109.6	C14—C13—C12	119.2 (2)
C3—C2—H2B	109.6	C14—C13—H13	120.4
H2A—C2—H2B	108.1	C12—C13—H13	120.4
N4—C3—C2	109.7 (2)	C15-C14-C13	120.7(2)
N4—C3—H3A	109.7	C15-C14-H14	119.6
C2—C3—H3A	109.7	C13—C14—H14	119.6
N4—C3—H3B	109.7	C14-C15-C16	119.0 119.9(2)
$C_2$ — $C_3$ — $H_3B$	109.7	C14—C15—H15	120.0
$H_{3A}$ $-C_{3}$ $-H_{3B}$	108.2	C16—C15—H15	120.0
C42 - N4 - C3	120.7(2)	$C_{11} - C_{16} - C_{15}$	120.0 120.3(2)
C42 = N4 = C5	119 60 (18)	C11_C16_H16	110.8
$C_{42} = N_4 = C_5$	113.33 (17)	C15_C16_H16	119.8
N4 C5 C6	113.33(17) 100.75(10)	$C_{10}$ $C$	119.0
N4 C5 H5A	109.73 (19)	N41 C42 N43	110.0(2)
$\Gamma = C_{5} = \Pi_{5} \Lambda$	109.7	N41 - C42 - N43	120.0(2)
$C_0 - C_5 - H_5 P$	109.7	N41 - C42 - N4	110.7(2) 117.2(2)
M4 - C3 - H5B	109.7	1143 - 042 - 114	117.3(2) 115.3(2)
	109.7	V44 - N43 - C42	113.3(2)
NI C( C5	108.2	N43 - C44 - C43	123.8 (2)
	109.6 (2)	N43-C44-H44	118.1
N1 - C6 - H6A	109.8	C45—C44—H44	118.1
	109.8	C44 - C45 - C46	115.8 (2)
$N1 - C_0 - H_0 B$	109.8	C44—C45—H45	122.1
С5—С6—Н6В	109.8	C46—C45—H45	122.1
H6A—C6—H6B	108.2	N41—C46—C45	123.1 (2)
017—C17—N1	123.3 (2)	N41—C46—H46	118.5
	118.59 (19)	C45—C46—H46	118.5
NI-CI7-CII	118.07 (19)		
C17—N1—C2—C3	116.2 (3)	C17—C11—C12—I12	-7.2 (3)
C6—N1—C2—C3	-56.4 (3)	C11—C12—C13—C14	-0.6 (3)
N1-C2-C3-N4	54.1 (3)	I12—C12—C13—C14	-179.83 (16)
C2-C3-N4-C42	151.8 (2)	C12—C13—C14—C15	0.6 (3)
C2—C3—N4—C5	-56.4 (3)	C13—C14—C15—C16	-0.3 (4)
C42—N4—C5—C6	-150.6 (2)	C12—C11—C16—C15	0.1 (3)
C3—N4—C5—C6	57.3 (3)	C17—C11—C16—C15	-173.4 (2)
C17—N1—C6—C5	-116.3 (2)	C14—C15—C16—C11	-0.1 (4)
C2—N1—C6—C5	56.8 (3)	C46—N41—C42—N43	-1.0 (4)
N4-C5-C6-N1	-55.3 (2)	C46—N41—C42—N4	177.6 (2)
C2—N1—C17—O17	-173.7 (3)	C3—N4—C42—N41	175.3 (2)
C6—N1—C17—O17	-1.6 (4)	C5—N4—C42—N41	25.3 (3)
C2—N1—C17—C11	6.0 (4)	C3—N4—C42—N43	-6.0 (3)
C6—N1—C17—C11	178.1 (2)	C5—N4—C42—N43	-156.1 (2)
O17—C17—C11—C16	94.4 (3)	N41—C42—N43—C44	1.1 (4)

# supporting information

N1—C17—C11—C16	-85.3 (3)	N4—C42—N43—C44	-177.5(2)
O17—C17—C11—C12	-78.9 (3)	C42—N43—C44—C45	-0.7 (4)
N1—C17—C11—C12	101.4 (3)	N43—C44—C45—C46	0.4 (4)
C16—C11—C12—C13	0.2 (3)	C42—N41—C46—C45	0.5 (4)
C17—C11—C12—C13	173.52 (19)	C44—C45—C46—N41	-0.3 (4)
C16—C11—C12—I12	179.44 (16)		

Hydrogen-bond geometry (Å, °)

# Cg1 is the centroid of the C11–C16 ring.

D—H···A	<i>D</i> —Н	H···A	D···· $A$	D—H···A	
C13—H13…O17 <sup>i</sup>	0.95	2.40	3.160 (3)	136	
C16—H16…O17 <sup>ii</sup>	0.95	2.50	3.395 (3)	157	
C45—H45…O17 <sup>iii</sup>	0.95	2.57	3.508 (3)	169	
C46—H46··· $Cg1^{iv}$	0.95	2.72	3.596 (3)	153	

Symmetry codes: (i) -x+1/2, y-1/2, -z+1/2; (ii) -x+1, -y+1, -z+1; (iii) x, y, z+1; (iv) -x+1/2, y+1/2, -z+3/2.